🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. Cervarix™

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 mab completed

    1 trial

  2. Chemotherapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 3 small molecule completed

    1 trial

  3. Chemotherapy + avelumab followed by avelumab + talazoparib

    Pfizer

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  4. Chemotherapy drug

    Chinese PLA General Hospital

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  5. Chirhostim

    The George Institute

    Pancreatic cancer, Intraductal papillary mucinous intraductal neoplasia

    phase 3 small molecule active

    1 trial

  6. Chronocort®

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    5 trials

  7. Cibinqo 100 mg film-coated tablets, Placebo for Abrocitinib 100mg tablet

    Pfizer Australia Pty Ltd

    Moderate to severe atopic dermatitis

    phase 3 small molecule active

    1 trial

  8. Cidofovir, Brincidofovir

    Lacuna Pharma Pty Ltd

    Adenovirus viremia

    phase 3 small molecule active

    1 trial

  9. Cilostazol-Elpen 100 mg Tabletten, Placebo de Cilostazol-Elpen 100mg, comprimé

    Pari Pharma GmbH

    Aneurysmal Subarachnoid Hemorrhage

    phase 3 small molecule active

    1 trial

  10. Cilta-cel

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. Cimzia 200 mg solution for injection in pre-filled syringe, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adult women with recurrent implantation failures (RIF)

    phase 3 small molecule active

    1 trial

  12. Cipaglucosidase Alfa

    AMICUS THERAPEUTICS PTY LTD

    Pompe Disease (Late-onset)

    phase 3 mab completed

    1 trial

  13. Ciprofloxacin (BAYQ3939) dry powder for inhalation

    Bayer HealthCare AG

    Bronchiectasis

    phase 3 small molecule completed

    1 trial

  14. Cisplatin

    Children's Hospital of Fudan University

    Localized Osteosarcoma

    phase 3 small molecule completed

    1 trial

  15. Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Squamous Cell Carcinoma of Head and Neck

    phase 3 small molecule active

    1 trial

  16. Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule completed

    1 trial

  17. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  18. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Ningbo Cancer Hospital

    Advanced head and neck cancer

    phase 3 small molecule active

    1 trial

  19. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer (CM), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 2927088, BAY 2927088 Bayer (CM), Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer

    Bayer AG

    Advanced non-small cell lung cancer with HER2 (ERBB2) mutation

    phase 3 small molecule active

    1 trial

  20. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial

  21. Cladribine (MAVENCLAD®)

    United Therapeutics Europe Ltd

    Advanced Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  22. Clamp-Crushing technique

    The First People's Hospital of Lianyungang

    Hepatobiliary Disease

    phase 3 other completed

    1 trial

  23. Clascoterone

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acne Vulgaris

    phase 3 small molecule active

    1 trial

  24. Claseprubart

    Dianthus Therapeutics, Inc. /DE/

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources